The power of humans being proud

News & Media

The power of humans being proud

We are always excited to share good news.

PRESS RELEASE December 1, 2017

Dr. Reddy’s Announces Approval of Impoyz(clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval

Princeton, NJ

Learn more

 

PRESS RELEASE November 15, 2017

Promius Pharma Announces ZEMBRACE® SymTouch® (Sumatriptan Injection) 3 mg Achieves Primary Endpoint in Post-Approval Clinical Trial

Princeton, NJ

Learn more

 

PRESS RELEASE November 9, 2017

Promius Pharma Initiates Phase 3 Clinical Trials of DFD-03 for The Treatment of Acne Vulgaris

Princeton, NJ

Learn more

 

PRESS RELEASE October 13, 2017

Focus on psoriasis; Promius Pharma announces 4 posters regarding SERNIVO® (betamethasone dipropionate) Spray, 0.05% at Fall Clinical Dermatology Conference®

Princeton, NJ

Learn more

 

PRESS RELEASE October 13, 2017

Announcing progress in dermatological research, Promius Pharma shares 9 posters at Fall Clinical Dermatology Conference®

Princeton, NJ

Learn more

 

PRESS RELEASE September 29, 2017

Promius Pharma Named PM360 Silver Winner Trailblazer Specialty Pharma/Biotech Company of the Year

Princeton, NJ

Learn more

 

PRESS RELEASE September 12, 2017

Promius Pharma Named PM360 Trailblazer 2017 Company of the Year for Specialty Pharma/Biotech Finalist and Marketing Team of the Year Finalist

Princeton, NJ

Learn more

 

PRESS RELEASE September 12, 2017

Promius Pharma’s Harshal Deshpande Named PM360 Trailblazer 2017 Brand Champion for Pain/Inflammation

Princeton, NJ

Learn more

 

PRESS RELEASE September 7, 2017

Promius Pharma to Present 3 Posters, Including a Podium Presentation, from MAST Study—the Largest Online Longitudinal Epidemiological Survey of Episodic/Chronic Migraine in the United States

Princeton, NJ

Learn more

 

PRESS RELEASE September 7, 2017

Promius Pharma Presents Positive Results for Phase 2 Study of DFN-02, a Novel Intranasal Formulation of Sumatriptan, at 18th Congress of the International Headache Society

Princeton, NJ

Learn more

 

PRESS RELEASE June 23, 2017

Promius Pharma Launches No Time 4 Migraines PSA to Educate Patients and Caregivers During Migraine Awareness Month

Princeton, NJ

Learn more

 

PRESS RELEASE June 9, 2017

Migraine Research Team, Including Dr Sagar Munjal and Dr Alix Bennett of Promius Pharma, Honored at AHS 2017 With the Harold G. Wolff Lecture Award

Princeton, NJ

Learn more

 

PRESS RELEASE June 8, 2017

Promius Pharma to Present Two Posters From MAST Study, the Largest Online Longitudinal Epidemiological Survey of Episodic/Chronic Migraine in the United States

Princeton, NJ

Learn more

 

PRESS RELEASE June 6, 2017

Promius Pharma Announces Positive Results for Phase 2 Study of DFN-02, a Novel Intranasal Formulation of Sumatriptan

Princeton, NJ

Learn more

 

PRESS RELEASE June 6, 2017

Promius Pharma to Present Innovative Scientific Results From Migraine Studies at the 59th Annual Scientific Meeting of the American Headache Society

Princeton, NJ

Learn more

 

PRESS RELEASE August 18, 2016

Promius Pharma Launches NoTime4Migrines, An Online Resource About Migraine Symptoms and Potential Treatment Options

Princeton, NJ

Learn more

 

PRESS RELEASE April 19, 2016

FDA approved ZEMBRACE SymTouch (sumatriptan injection) 3 mg in January 2016 for the acute treatment of migraine with or without aura in adults. ZEMBRACE SymTouch is now commercially available in the U.S.

Hyderabad, India and Princeton, NJ, USA

Learn more

 

PRESS RELEASE April 15-21, 2016

Promius Pharma Will Present Results of Additional Analysis of the American Migraine Prevalence and Prevention Study (AMPP) in Vancouver at the 68th AAN Annual Meeting

Hyderabad, India and Princeton, NJ, USA

Learn more

 

PRESS RELEASE March 18, 2016

Promius Pharma Presents New Data Around Sernivo™ (betamethasone dipropionate) Spray, 0.05%

Princeton, NJ

Learn more

 

PRESS RELEASE February 8, 2016

Promius Pharma Receives FDA Approval for Sernivo (betamethasone dipropionate) Spray, 0.05%

Hyderabad, India and Princeton, NJ, USA

Learn more

 

PRESS RELEASE February 1, 2016

Dr. Reddy’s Laboratories Receives USFDA Tentative Approval for Zenavod™ (doxycycline) Capsules, 40 mg for the Treatment of Rosacea in Adults

Hyderabad, India and Princeton, NJ, USA

Learn more

 

PRESS RELEASE January 29, 2016

Dr. Reddy’s Laboratories Ltd. and its U.S. subsidiary Promius Pharma™ LLC receive FDA approval for ZEMBRACESymTouch (sumatriptan injection) 3 mg for the acute treatment of migraines in adults

Hyderabad, India and Princeton, NJ, USA

Learn more

 

PRESS RELEASE October 20, 2015

Promius Pharma Presents Clinical Data From Two Phase III Studies Of DFD-01 For the Treatment of Moderate Psoriasis

Princeton, NJ

Learn more

 

PRESS RELEASE September 14, 2015

Dr. Reddy’s Laboratories signs commercialization deal with Hatchtech

Hyderabad, India

Learn more

 

PRESS RELEASE June 29, 2015

The Promius Promise Helps Physicians be More Proactive in Treating Patients With Acne

Princeton, NJ

Learn more

 

PRESS RELEASE June 1, 2015

The Promius Promise Now Offers Even More

Princeton, NJ

Learn more

 

PRESS RELEASE April 7, 2015

Dr. Reddy’s Laboratories and its subsidiary Promius Pharma announce the filing of three NDAs with the USFDA

Hyderabad, India and Princeton, NJ, USA

Learn more

 

PRESS RELEASE March 5, 2015

TRIANEX 0.05% (Triamcinolone Acetonide Ointment,USP) Now Available from Promius Pharma, LLC

Princeton, NJ

Learn more

 

PRESS RELEASE March 5, 2015

Promius Promise Announces Zentatane™ (Isotretinoin Capsules USP) 30mg

Princeton, NJ

Learn more

 

PRESS RELEASE January 14, 2015

Promius Pharma expands the reach of The Promius Promise with a new app for isotretinoin patients

Hyderabad, India and Princeton, NJ, USA

Learn more

 

PRESS RELEASE October 17, 2014

Promius Pharma marks milestone for The Promius Promise

Hyderabad, India and Princeton, NJ, USA

Learn more